Dynamic Humoral Immune Response to Primary and Booster Inactivated SARS-CoV-2 Vaccination in Patients with Cirrhosis

作者全名："Zhu, Qian; Wang, Lu; Hu, Xiaoxiao; Zhang, Yingzhi; Huang, Tianquan; He, Taiyu; Chen, Zhiwei; Zhang, Gaoli; Peng, Mingli; Chen, Min; Cai, Dachuan; Shi, Xiaofeng; Ren, Hong"

作者地址："[Zhu, Qian; Wang, Lu; Hu, Xiaoxiao; Zhang, Yingzhi; Huang, Tianquan; He, Taiyu; Chen, Zhiwei; Zhang, Gaoli; Peng, Mingli; Chen, Min; Cai, Dachuan; Shi, Xiaofeng; Ren, Hong] Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Dept Infect Dis,Key Lab Mol Biol Infect Dis,Minist, Chongqing, Peoples R China; [Shi, Xiaofeng; Ren, Hong] 288 Tianwen Ave, Chongqing 401336, Peoples R China"

通信作者："Shi, XF; Ren, H (通讯作者)，288 Tianwen Ave, Chongqing 401336, Peoples R China."

来源：JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY

ESI学科分类：　

WOS号：WOS:001059383500001

JCR分区：Q2

影响因子：3.1

年份：2023

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Article; Early Access

关键词：SARS-CoV-2; Omicron subvariants; Cirrhosis; Booster dose; Hu-moral response

摘要："Background and Aims: Our aim was to determine the im mune efficacy of a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) booster vaccination in cirrhotic patients who had received the primary series. Methods: We performed a longitudinal assessment in 48 patients with cirrhosis, 57 patients with chronic hepatitis B (CHB) and 68 healthy controls (HCs) to continuously track the dynamics of SARS-CoV-2 specific antibodies and memory B cells after receiving the primary series and booster dose at different times. A pseudovirus neutralization assay was used to determine neutralization against Omicron subvariants BA.2.12.1, BA.4 and BA.5 from serum samples collected from three cohorts. Results: Serum anti-receptor-binding domain (RBD) immunoglobulin (Ig)G and neutralizing antibody (NAb) levels in cirrhotic patients were elevated within 15-45 days after completing the primary series before rapidly declining and reaching a valley at around 165-195 days. After receiving the booster dose, both antibody levels were significantly increased to levels comparable to patients with CHB and HCs. Subgroup analysis showed that booster vaccination induced weaker antibody responses in patients with decompensated cirrhosis than in those with compensated cirrhosis. The SARS-CoV-2 memory B-cell response in cirrhotic patients was durable during follow-up regardless of the hepatic fibrocirrhosis grade. However, compared with the primary series, the booster dose did not result in an evident improvement of neutralization activity against the Omicron subvariants BA.2.12.1 and BA.4, and was followed by a significant de- crease in the titer against BA.5. Conclusions: A booster dose elicited a robust and durable humoral response to the wild-type strain in cirrhotic patients but not the Omicron sub- variants. Repeated vaccination of inactivated SARS-CoV-2 vaccine may not benefit cirrhotic patients in neutralization against newly circulating strains."

基金机构："National Science and Technology Major Project of China [2017 ZX10202203-008, 2018ZX10302206-003, 81772198]; Second Affiliated Hospital of Chongqing Medical University; First batch of key Disciplines On Public Health in Chongqing; National Natural Science Foundation of China [cstc2020jcyj-msxmX0389]; Natural Science Foundation of Chongqing, China; Remarkable Innovation-Clinical Research Project; [2017ZX10202203-007]"

基金资助正文："This work was supported by the National Science and Technology Major Project of China (2017ZX10202203-007, 2017 ZX10202203-008, 2018ZX10302206-003) , Remarkable Innovation-Clinical Research Project, The Second Affiliated Hospital of Chongqing Medical University and The First batch of key Disciplines On Public Health in Chongqing. We also acknowledge the support of the National Natural Science Foundation of China (81772198) , Natural Science Foundation of Chongqing, China (cstc2020jcyj-msxmX0389) ."